¹⁸F-fluorodeoxyglucose PET in Major Psychiatric Disorders

¹⁸F-fluorodeoxyglucose (FDG)-PET offers a systems-level view of brain dysfunction in psychiatry, with findings more informative at the circuit and network level than as fixed disease-specific patterns. In schizophrenia, addictions, and mood disorders, reproducible abnormalities involve prefrontal, limbic, striatal, and multimodal associative networks, although their expression depends on clinical state, stage, treatment, and comorbidity. This review summarizes principal FDG-PET findings in major psychiatric disorders and integrates them with selected molecular imaging data. Although FDG-PET is not a diagnostic test for primary psychiatric disorders, it aids in complex cases by supporting phenotyping and distinguishing psychiatric illness from neurodegenerative and other brain disorders.